摘要
用抗膀胱癌免疫毒素（BDI-1-MD）行膀胱癌灌注20例，治疗膀胱癌及预防膀胱癌复发，其中16例（Ⅰ组）于术后进行灌注，4例多发性膀胱肿瘤（Ⅱ组）直接行灌注。Ⅰ组中，膀胱肿瘤Ⅰ级4例，Ⅰ～Ⅱ级5例，Ⅱ级4例，Ⅱ～Ⅲ级3例。初发肿瘤13例，复发肿瘤3例。Ⅱ组中，Ⅲ～Ⅲ级1树，Ⅲ级3例。初发肿瘤3例，复发肿瘤1例。平均随访12．3个月，Ⅰ组仅1例8个月后复发（复发率6．3％）。Ⅱ组中，有效2例，弱效2例。未见灌注引起的毒副反应，免疫指标无异常。表明BDI-1-MD对膀胱肿瘤有强杀伤能力和高度特异性，而对正常组织无损伤。提示此免疫毒素对治疗膀胱癌及预防术后复发有良好的作用。
20 patients with bladder carcinoma were treated with intravesical administration of im-munotoxin (BDI-1-MD). Group Ⅰ(16 cases) were conducted postoperatively, while group,Ⅱ (4 cases )with multiple bladder carcinomas were treated directly. In group Ⅰ4,5 and 3 patients were with gradeⅠ，Ⅱ and Ⅱ ~Ⅲ tumors,respectively. 13 cases had primary carcinoma,and 3 with recurrent tumor.One had grade Ⅱ~Ⅲ tumor,whereas 3 with gradeⅢin group Ⅱpatients. 3 of these 4 cases had pri-mary carcinoma,and 1 had recurrent tumou. The patients were followed up for an average period of l2.3months. In group Ⅰ, l5 cases were free from recurrence except one(6.3% ). In groupⅡ,2 cases showedpartial response,while the other 2 revealed minor response. No side effect was found. The results indi-cate that BDI-1-MD can specifically kill bladder tumor cells. Immunotoxin might be effective in thetreatment and prevention of recurrence of human bladder carcinoma.
出处
《江苏医药》
CAS
CSCD
1999年第12期907-909,共3页
Jiangsu Medical Journal
基金
卫生部临床学科重点项目!97-195
南京市科委科研基金!99-23
